{"entity":{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","aka":["NEJM Evid"],"tldr":"NEJM Group's newer journal for clinical trials and trial methodology, publishing rigorous randomised studies that fall just outside the parent journal's remit.","summary":"NEJM Evidence (NEJM Evid) is the NEJM Group's newer journal for clinical trials and trial methodology, appearing monthly since 2022 and published by the NEJM Group / Massachusetts Medical Society on a subscription basis with the group's editorial standards. It publishes rigorous randomised trials that fall just outside the parent journal's remit, pragmatic and adaptive designs, and methods pieces including the Stats, STAT! series and trial-design tutorials, with oncology studies on dosing, de-escalation and screening. Its readers are clinicians and trialists who care about trial design as much as results. Within OnCo it is linked from the biographies of Do-Youn Oh, Ghassan Abou-Alfa and Daniel Spratt, and a reader would use it for oncology trials on dosing and de-escalation.","asOf":"2026-09-09","links":[{"label":"NEJM Group","url":"https://www.nejmgroup.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"NEJM Group / Massachusetts Medical Society","url":"https://evidence.nejm.org","issn":"2766-5526","scope":"general medicine","access":"subscription","founded":2022,"matchNames":["NEJM Evidence","NEJM Evid"],"society":"Massachusetts Medical Society"},"route":"/journals/nejm-evidence/","neighbours":{"person":[{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","route":"/people/daniel-spratt/"},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/"},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/"}],"paper":[{"id":"paper-clarke-nejm-evid","kind":"paper","name":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-clarke-nejm-evid/"},{"id":"paper-barnabas-nejm-evid","kind":"paper","name":"Efficacy of single-dose HPV vaccination among young African women","route":"/key-papers/paper-barnabas-nejm-evid/"},{"id":"paper-himalaya-nejm-evidence-2022","kind":"paper","name":"HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","route":"/key-papers/paper-himalaya-nejm-evidence-2022/"},{"id":"paper-chamie-nejm-evid","kind":"paper","name":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","route":"/key-papers/paper-chamie-nejm-evid/"},{"id":"paper-smith-nejm-evid","kind":"paper","name":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery","route":"/key-papers/paper-smith-nejm-evid/"},{"id":"paper-ipss-m-bernard-nejm-evidence-2022","kind":"paper","name":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","route":"/key-papers/paper-ipss-m-bernard-nejm-evidence-2022/"},{"id":"paper-relativity-047-nejm-evid-2023-update","kind":"paper","name":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","route":"/key-papers/paper-relativity-047-nejm-evid-2023-update/"},{"id":"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023","kind":"paper","name":"PIONEER: avapritinib versus placebo in indolent systemic mastocytosis","route":"/key-papers/paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023/"},{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/"},{"id":"paper-topaz-1-nejm-evidence-2022","kind":"paper","name":"TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","route":"/key-papers/paper-topaz-1-nejm-evidence-2022/"}]}}